{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:39Z","timestamp":1791614979871,"version":"4.3.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perfusion"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Two previous clinical studies indicated veno-venous perfusion-induced systemic hyperthermia (VV-PISH), producing elevated temperatures of 42\u00b0C, induces cell death, apoptosis, or senescence of responsive cancers. The VV-PISH circuit has been refined and rebranded as Hyperthermic Extracorporeal Applied Tumor Treatment (HEATT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The local IRB approved this retrospective chart review. All devices are FDA-approved. The referring physician judged each patient to be hospice-eligible with a median predicted survival of 3\u00a0months and maximum predicted survival of 6\u00a0months. We evaluated HEATT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      in hospice-eligible patients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 13) with unresponsive, advanced cancer, conducted at a single site, with a select, consistent team of healthcare providers (critical care, anesthesia, perfusionist, interventional radiologist, HEATT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      consultant). HEATT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      treatment (42\u00b0C for 120\u00a0min) was delivered once between June 2021 and April 2022. The referring physician followed patients until documented death. HEATT circuit and criteria were refined to maximize safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In a retrospective chart review of the 13 consecutive patients, 8\/13 patients exceeded expected median survival, 6\/13 exceeded the 6-months predicted end-of-life, and 5\/13 exceeded 12\u00a0months. Lessons learned allowed the refinement of inclusion\/exclusion criteria of Karnofsky &gt;70, ability to ambulate, and age &lt;80. Likewise, refining the circuitry led to improved standardization of the HEATT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      perfusion technique and management.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This consecutive series of 13 hospice-eligible patients demonstrated the refinement of HEATT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , focusing on perfusion technique and selection criteria. In this small series of physician-referred hospice-eligible patients unresponsive to conventional therapy or other integrative oncology treatments, HEATT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      demonstrated safety with an increase in the length of survival over median expected in eight of 13 patients, with five of 13 patients living 12 to 18\u00a0months, 2-3 times longer than the referring physician expected. These refinements are essential to enable prospective randomized trials of like-patient populations to generate evidence-based medical recommendations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02676591251413475","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:40:44Z","timestamp":1767904844000},"page":"1215-1222","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT\n                    <sup>\u00ae<\/sup>\n                    ) in hospice-eligible cancer patients"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-2571","authenticated-orcid":false,"given":"Joseph B.","family":"Zwischenberger","sequence":"first","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyton","family":"Mashni","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fischer","sequence":"additional","affiliation":[{"name":"First Baptist Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Essa","sequence":"additional","affiliation":[{"name":"First Baptist Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hatchett","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Winetz","sequence":"additional","affiliation":[{"name":"Verthermia Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Vertrees","sequence":"additional","affiliation":[{"name":"Verthermia Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(19)38032-8"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00846-9"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(01)02673-X"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002480-199607000-00004"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002480-199703000-00114"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(00)01381-3"},{"key":"e_1_3_5_8_2","first-page":"349","article-title":"Development of a human to murine orthotopic xenotransplanted lung cancer model","volume":"13","author":"Vertrees RA","year":"2000","unstructured":"Vertrees RA, Deyo DJ, Quast M, et al. Development of a human to murine orthotopic xenotransplanted lung cancer model. J Invest Surg 2000; 13: 349\u2013358.","journal-title":"J Invest Surg"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/026765910101600310"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2003.10.111"},{"key":"e_1_3_5_11_2","unstructured":"Investigational device exemption report IDE G130024 6\/13\/2022."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.24406"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534735419876345"},{"key":"e_1_3_5_14_2","first-page":"e34100","article-title":"Hyperthermic extracorporeal applied tumor therapy for six cycles for recurrent metastatic peritoneal serous papillary carcinoma","volume":"15","author":"Vertrees RA","year":"2023","unstructured":"Vertrees RA, Zwischenberger JB, Winetz JA. Hyperthermic extracorporeal applied tumor therapy for six cycles for recurrent metastatic peritoneal serous papillary carcinoma. Cureus 2023; 15: e34100.","journal-title":"Cureus"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2013.807440"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2727"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24749-6"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20124"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/02656730500204487"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0b013e318271badb"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.04.023"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2020.01.001"}],"container-title":["Perfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02676591251413475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02676591251413475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02676591251413475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:18:42Z","timestamp":1791613122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02676591251413475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/02676591251413475"],"URL":"https:\/\/doi.org\/10.1177\/02676591251413475","relation":{},"ISSN":["0267-6591","1477-111X"],"issn-type":[{"value":"0267-6591","type":"print"},{"value":"1477-111X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}